Heat Biologics Inc. believes that its heat shock protein technology for cancer immunotherapy may have an advantage over competitors because it exposes the immune system to all of a cancer's antigens, whereas other treatments only use a select number of antigens.

Heat's lead therapy is HeatShock gp96-Ig, which is in Phase I/II testing for non-small cell lung cancer (NSCLC). The therapy involves the intra-dermal injection of a live attenuated, immortalized NSCLC tumor cell that has been engineered to function as a vaccine-producing cell.